基于电子健康记录的房颤风险引导筛查模型 FIND-AF 2.0
该研究开发并在英国、日本、以色列、加拿大和中国电子健康记录中验证了预测 6 个月内新发房颤的随机森林模型 FIND-AF 2.0。前瞻性研究纳入 1923 名卒中风险升高且无房颤的参与者,高风险组房颤检出率为 4.5%,低风险组为 0.6%。该模型可识别适合房颤筛查的高风险人群。
要点
- FIND-AF 2.0 在各队列预测新发房颤的 AUROC 均超过 0.7。
- 高风险组房颤检出率 4.5%,为低风险组的 8.46 倍。
- 高风险检出者中 96.1% 启动了口服抗凝治疗。
核心结论
- 基于电子健康记录的机器学习模型 FIND-AF 2.0 可识别卒中风险升高患者中房颤诊断的高风险亚群。
- 该模型有望支持可扩展的、由电子健康记录驱动的房颤风险引导筛查。
研究设计与样本
- 开发并外部验证随机森林预测模型,预测 6 个月内新发房颤,变量包括年龄、性别和 10 种合并症。
- 验证队列来自英国、日本、以色列、加拿大和中国的电子健康记录。
- 前瞻性研究纳入 1923 名年龄≥30 岁、无房颤且卒中风险升高的参与者,按 FIND-AF 2.0 分为高风险和低风险组。
- 参与者使用手持心电记录仪每天记录 4 次心电图,持续 3 周,主要结局为新诊断房颤。
- 利用 Finnish Anticoagulation in Atrial Fibrillation 注册研究评估高风险 FIND-AF 2.0 房颤患者未抗凝时的缺血性卒中风险。
主要发现
- FIND-AF 2.0 在英国队列 AUROC 为 0.819(95% CI,0.809-0.829),以色列为 0.835(95% CI,0.828-0.842)。
- 日本队列 AUROC 为 0.751(95% CI,0.745-0.757),加拿大为 0.747(95% CI,0.741-0.753),中国为 0.753(95% CI,0.725-0.771)。
- 所有队列中男性和女性 AUROC 均超过 0.7,且预测性能优于 CHA2DS2-VASc 和 C2HEST。
- 前瞻性研究参与者平均年龄 70.2 岁,平均记录 74.8 次心电图;低风险组 902 人中 5 人(0.6%)诊断为房颤,高风险组 1021 人中 46 人(4.5%)诊断为房颤。
- 高风险检出病例的房颤负荷中位数为 33.4%(四分位距,5.1%-91.6%),96.1% 启动口服抗凝治疗。
关键数值与推荐
- 高风险组与低风险组房颤检出比值比为 8.46(95% CI,3.35-21.40),P<0.001。
- 前瞻性研究纳入标准为年龄≥30 岁、无房颤、男性 CHA2DS2-VASc≥2 分或女性 CHA2DS2-VASc≥3 分。
临床怎么用
- FIND-AF 2.0 可用于在卒中风险升高人群中筛选房颤筛查的优先对象。
- 高风险组检出房颤后口服抗凝启动率较高,提示该策略可能转化为卒中预防机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Screening for atrial fibrillation (AF) on the basis of AF risk may be more effective. We aimed to develop, externally validate, and prospectively test a machine learning prediction model using electronic health records (EHRs) to guide AF screening. METHODS: We developed and validated a random forest prediction model for new AF within 6 months, using age, sex, and 10 comorbidities (Future Innovations in Novel Detection of Atrial Fibrillation [FIND-AF] 2.0) in EHRs in the United Kingdom (n=2 081 139), Japan (n=7 795 244), Israel (n=2 166 795), Canada (n=627 919), and China (n=149 145). We conducted a prospective study where participants ≥30 years old without AF and with a CHA2DS2-VASc score ≥2 in men and ≥3 in women, stratified by FIND-AF 2.0 into high and low risk, undertook 4 ECG recordings per day for 3 weeks using a handheld ECG recorder, with a primary outcome of newly diagnosed AF. We estimated stroke risk associated with nonanticoagulated AF in patients with high FIND-AF 2.0 risk in the FinACAF (Finnish Anticoagulation in Atrial Fibrillation) registry of patients with AF (n=229 565). RESULTS: FIND-AF 2.0 was applicable to all EHRs and showed good to excellent prediction performance (United Kingdom: area under the receiver operating characteristic curve [AUROC], 0.819 [95% CI, 0.809-0.829]; Israel: AUROC, 0.835 [95% CI, 0.828-0.842]; Japan: AUROC, 0.751 [95% CI, 0.745-0.757]; Canada: AUROC, 0.747 [95% CI, 0.741-0.753]; China: AUROC, 0.753 [95% CI, 0.725-0.771]), with AUROC>0.7 in men and women in all cohorts, and improved performance compared with CHA2DS2-VASc and C2HEST (coronary artery disease or chronic obstructive pulmonary disease [1 point each]; hypertension [1 point]; elderly [age ≥75 years, 2 points]; systolic HF [2 points]; thyroid disease [hyperthyroidism, 1 point]). Of 1923 participants from 15 sites in the prospective study (mean age, 70.2 [SD 9.4] years), with a mean of 74.8 (SD, 19.4) ECG recordings, AF was diagnosed in 5 of 902 (0.6%) with low FIND-AF 2.0 risk and 46 of 1021 (4.5%) with high FIND-AF 2.0 risk (odds ratio, 8.46 [95% CI, 3.35-21.40], P<0.001). Median AF burden among high FIND-AF 2.0 risk-detected cases was 33.4% (interquartile range, 5.1%-91.6%), and 96.1% initiated oral anticoagulants. In the FinACAF registry, the rate of ischemic stroke for patients with high FIND-AF 2.0 risk, AF, and no anticoagulants was 6.0 events per 100 patient-years. CONCLUSIONS: The EHR-based machine learning model, FIND-AF 2.0, identifies a high-risk subpopulation for AF diagnosis among patients at elevated risk of stroke and could enable scalable, EHR-driven, risk-guided AF screening.
引用
- Nadarajah, Wu, Wahab, et al. Risk-Guided Screening for Atrial Fibrillation Using Electronic Health Records. Circulation. 2026. PMID: 42517218. doi:10.1161/CIRCULATIONAHA.126.079391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。